Breaking News Instant updates and real-time market news.

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

, SCS

Steelcase

$17.49

-0.115 (-0.65%)

19:06
03/19/19
03/19
19:06
03/19/19
19:06

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Smartsheet (SMAR) up 10.1%... Steelcase (SCS) up 6.3%... Aurinia Pharma (AUPH) up 3.3%. ALSO HIGHER: Nevro Corp (NVRO) up 7.2% after announced CEO replacement... Sage Therapeutics (SAGE) up 4.4% after FDA approval of Zulresso. DOWN AFTER EARNINGS: Tencent Music (TME) down 7.5%... Wextport Fuel Systems (WPRT) down 7.3%... AAR Corp (AIR) down 5.7%... FedEx (FDX) down 5.6%... Franco-Nevada (FNV) down 2.2%... Principia Biopharma (PRNB) down 1.2%. Movers as of 18:45ET.

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

SCS

Steelcase

$17.49

-0.115 (-0.65%)

AUPH

Aurinia Pharmaceuticals

$6.40

0.13 (2.07%)

NVRO

Nevro

$44.76

0.37 (0.83%)

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

TME

Tencent Music

$18.65

-0.48 (-2.51%)

WPRT

Westport

$1.50

(0.00%)

AIR

AAR Corp.

$35.10

(0.00%)

FDX

FedEx

$181.50

-0.92 (-0.50%)

FNV

Franco-Nevada

$75.64

0.035 (0.05%)

PRNB

Principia Biopharma

$36.88

0.48 (1.32%)

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 01

    Apr

  • 02

    Apr

  • 05

    Apr

  • 14

    May

  • 28

    May

  • 24

    Jun

  • 26

    Jun

SMAR Smartsheet
$43.51

-0.16 (-0.37%)

01/03/19
SPHN
01/03/19
INITIATION
SPHN
Overweight
Smartsheet initiated with an Overweight at Stephens
Stephens analyst Dmitry Netis initiated Smartsheet with an Overweight rating and a price target of $32. The analyst believes Smartsheet's medium- to long-term growth prospects are strong, due to the company's platform growing across all lines of business, its highly effective land-and-expand strategy, and its continued push upmarket.
12/17/18
WBLR
12/17/18
NO CHANGE
WBLR
Outperform
William Blair remains bullish on Smartsheet after management meetings
William Blair analyst Bhavan Suri remains bullish on Smartsheet after meeting with management. The overall tone of the meetings was positive and management appeared upbeat about the company's momentum and growth opportunities heading into fiscal 2020, Suri tells investors in a research note. The analyst came away with greater confidence in Smartsheet's product roadmap and go-to-market strategy. He keeps an Outperform rating on the shares.
11/30/18
RBCM
11/30/18
NO CHANGE
Target $34
RBCM
Outperform
Smartsheet price target lowered to $34 from $39 at RBC Capital
RBC Capital analyst Ross MacMillan lowered his price target on Smartsheet to $34 to reflect the multiple compression across its peer group. The analyst also keeps his Outperform rating on the stock following a "positive" user conference last month, along with the conservatism in its model and consistent hiring. MacMillan expects the company to post another strong quarter when it reports Q3 results, driven by the momentum of its recent peer group event, product additions, and stepped up focus on its enterprise capabilities.
12/04/18
JEFF
12/04/18
NO CHANGE
Target $38
JEFF
Buy
Smartsheet easily exceeded Q3 expectations, says Jefferies
Jefferies analyst John DiFucci says Smartsheet easily exceeded fiscal Q3 expectations across all metrics on the back of accelerating new subscription annual contract value. Further, the company set guidance for Q4 above the Street, DiFucci tells investors in a post-earnings research note. The analyst continues to view Smartsheet as an "early leader in an immense opportunity enabling a broader user base to harness the power of technology, essentially providing an application development platform for white collar workers." He maintains a Buy rating on the shares with a $38 price target.
SCS Steelcase
$17.49

-0.115 (-0.65%)

10/12/18
GHSC
10/12/18
UPGRADE
Target $20
GHSC
Buy
Steelcase upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Matt McCall upgraded Steelcase to Buy from Neutral with a $20 price target citing cyclical, secular, and company specific opportunities. McCall said a "perfect storm" is setting-up from continued top-line momentum in commercial, minimal impact from tariffs and positive impact from the USMCA trade agreement, EMEA demand, several more quarters of easy comps, and reasonable valuation.
AUPH Aurinia Pharmaceuticals
$6.40

0.13 (2.07%)

08/13/18
HCWC
08/13/18
NO CHANGE
Target $15
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $15 after the company announced its pivotal Phase 3 study of voclosporin in lupus nephritis patients is running ahead of schedule. The analyst view the progress as a reflection of the high level of interest and motivation in the trial, by both patients and investigators. He keeps a Buy rating on Aurinia shares.
NVRO Nevro
$44.76

0.37 (0.83%)

02/22/19
BMOC
02/22/19
DOWNGRADE
Target $46
BMOC
Market Perform
Nevro downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Joanne Wuensch downgraded Nevro to Market Perform and kept her $46 price target after its Q4 earnings miss and a lower than expected outlook for FY19. The analyst points to the expected declines in revenues outside the U.S., driven by reimbursement changes in Australia, as well as the company's "minimal explanation" for this forecast, which she attributes to potential seasonality, sales rep hire dynamics, or the management's conservative outlook.
11/27/18
UBSW
11/27/18
INITIATION
UBSW
Sell
Nevro initiated with a Sell at UBS
UBS analyst Matthew Taylor initiated Nevro with a Sell rating and $35 price target, calling the stock a Top Sell. Taylor noted that Nevro's HF10 therapy has "changed the face of neuromod," but added that it has also "spurred competition from large, entrenched players."
11/07/18
11/07/18
DOWNGRADE
Target $45

Neutral
Nevro downgraded to Neutral on reduced growth at BofA/Merrill
As previously reported, BofA/Merrill downgraded Nevro to Neutral from Buy and slashed its price target to $45 from $77. Analyst Bob Hopkins said Nevro posted "strong" Q3 numbers but management comments on US volume growth in the spinal cord stimulation market were just 5-8%, causing shares to drop more than 16% yesterday. Hopkins is concerned that Nevro's outlook is much less than previously expected, and that management may have a weaker understanding on their market than anticipated.
11/27/18
11/27/18
INITIATION

Sell
Nevro initiated with a Sell at UBS
SAGE Sage Therapeutics
$156.08

-0.89 (-0.57%)

02/19/19
PIPR
02/19/19
NO CHANGE
Target $206
PIPR
Overweight
Piper sees 'significant unrealized value' in shares of Sage Therapeutics
Piper Jaffray analyst Danielle Brill keeps an Overweight rating on Sage Therapeutics with a $206 price target after the company reported fiscal 2018 results and an update on its pipeline. Enrollment in the SAGE-217 pivotal Phase 3 major depressive disorder trial is reportedly going well and top-line data are now expected by Q4 of 2019 or Q1 of 2020, Brill tells investors in a post-earnings research note. The analyst sees "significant unrealized value" for SAGE-217 and expects "various upcoming catalysts" to drive Sage shares higher.
02/22/19
GUGG
02/22/19
INITIATION
Target $205
GUGG
Buy
Sage Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated Sage Therapeutics with a Buy rating and $205 price target, as he believes Zulresso and SAGE-217 have generated impressive data in PPD and MDD. The analysts, who thinks those drugs "have the potential to change the treatment paradigm for treating mood disorders," projects Zulresso and SAGE-217 could generate sales in the $3B-$5B range.
01/07/19
PIPR
01/07/19
NO CHANGE
Target $206
PIPR
Overweight
Sage could be up over 50% folllowing 'clear win' in PPD, says Piper Jaffray
After Sage Therapeutics reported top-line results from the Phase 3 ROBIN study in women with postpartum depression, or PPD, Piper Jaffray analyst Danielle Brill said the data were "impressive and looked clean across the board" in a note titled "Clear Win as SAGE-217 Knocks It Out of the PPD Park." The analyst, who expects over 50% upside for Sage shares today, keeps an Overweight rating on the stock with a $206 price target. In pre-market trading, Sage Therapeutics shares are up $34.49, or 35%, to $132.
12/27/18
PIPR
12/27/18
NO CHANGE
Target $206
PIPR
Overweight
Sage's 217 PPD data to be 'important' inflection point in Q1, says Piper Jaffray
Piper Jaffray analyst Danielle Brill told investors in a research note that data from Sage Therapeutics' ongoing trial with 217 in postpartum depression will be an important inflection point for the company in 1Q19 and says she remains bullish ahead of the data. The analyst, who has an Overweight rating and $206 price target on Sage shares, says she is "comfortable" that 217's MOA and PK profiles are very closely related to brex and it should achieve similar anti-depressant effects in the ongoing pivotal PPD trial.
TME Tencent Music
$18.65

-0.48 (-2.51%)

01/18/19
01/18/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tencent Music (TME) initiated with a Buy at HSBC. 2. Wex (WEX) and FleetCor (FLT) were initiated with a Buy at BTIG. 3. Joint Corp (JYNT) initiated with a Buy at DA Davidson. 4. York Water (YORW) initiated with a Buy at Janney Montgomery Scott. 5. Primerica (PRI) initiated with an Outperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/17/19
HSBC
01/17/19
INITIATION
Target $16
HSBC
Buy
Tencent Music initiated with a Buy at HSBC
HSBC initiated Tencent Music with a Buy rating and a price target of $16.
02/12/19
MACQ
02/12/19
INITIATION
MACQ
Outperform
Tencent Music initiated with an Outperform at Macquarie
02/12/19
02/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Viavi (VIAV) initiated with an Outperform at Northland. 2. CECO Environmental (CECE) initiated with a Buy at B. Riley FBR. 3. Tencent Music (TME) initiated with an Outperform at Macquarie. 4. Enable Midstream (ENBL) initiated with a Neutral at Mizuho. 5. Elanco (ELAN) initiated with a Market Perform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
WPRT Westport
$1.50

(0.00%)

02/05/19
LSCM
02/05/19
DOWNGRADE
LSCM
Hold
Westport downgraded to Hold from Buy at Lake Street
01/15/19
HCWC
01/15/19
NO CHANGE
Target $6
HCWC
Buy
Westport CEO change shouldn't impact business plan, says H.C. Wainwright
After Westport Fuel Systems announced the appointment of David Johnson as CEO to replace Nancy Gougarty, who is retiring, H.C. Wainwright analyst Amit Dayal called the news "unexpected" but said he believes the company decided to act on the availability of Johnson, who is an auto industry veteran with a mechanical engineering background. Dayal does not expect any significant strategic changes under the new leadership and maintains his 2018 revenue and gross margin expectations. He keeps a Buy rating and $6 price target on Westport shares.
09/20/18
09/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Westport (WPRT) initiated with a Buy at H.C. Wainwright. 2. Legacy Reserves (LGCY) initiated with a Neutral at Seaport Global. 3. Tandem Diabetes (TNDM) initiated with a Buy at Craig-Hallum. 4. Bio-Rad (BIO) initiated with an Equal Weight at Morgan Stanley. 5. Brookfield (BAM) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/05/19
02/05/19
DOWNGRADE
Target $5

Hold
Lake Street downgrades Westport to Hold amid 'cloud of uncertainty'
As previously reported, Lake Street analyst Robert Brown downgraded Westport Fuel Systems to Hold from Buy, stating that the abrupt resignation of CFO Mike Willis following the changeover of CEO in January "creates a cloud of uncertainty." While he still views 2019 as an inflection year for Westport, citing expectations for the Volvo HPDI program and the Weichai HPDI engine launches, Brown said he needs time to gain confidence in the company's execution following the management changes. He lowered his price target on Westport shares to $5 from $6 and said he believes shares will be range-bound in the near-term.
AIR AAR Corp.
$35.10

(0.00%)

09/11/18
RHCO
09/11/18
DOWNGRADE
RHCO
Hold
AAR Corp. downgraded to Hold from Buy at SunTrust
09/11/18
RHCO
09/11/18
DOWNGRADE
Target $47
RHCO
Hold
AAR Corp. downgraded to Hold from Buy at SunTrust
As reported earlier, SunTrust analyst Michael Ciarmoli downgraded AAR Corp to Hold from Buy and lowered his price target to $47 from $50. The analyst notes that he is maintaining a bullish view on the aero aftermarket with an opportunity for AAR Corp to exploit its position while also reaping benefits from its INL Global Aviation Support Services contract, but he also believes that the company's near-term growth will come under pressure from its maintenance, repair, and overhaul, or MRO, segment. He cites tight labor condition in the unit as well as the delays associated with the company's new 737MAX/ A320NEO production, which combine to create a weaker than normal Q1 environment for AAR Corp.
09/11/18
09/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CBS (CBS) downgraded to Neutral from Buy at UBS with analyst John Hodulik saying uncertainty around the management transition limits upside in the shares and could last for an extended period. 2. Tesla (TSLA) downgraded to Neutral from Buy at Nomura Instinet with analyst Romit Shah expressing concern that the "erratic behavior" of CEO Elon Musk will taint the Tesla brand. 3. Johnson Controls (JCI) downgraded to Neutral from Buy at UBS with analyst Steven Winoker saying while the company's Buildings business is improving in 2018, the pace and magnitude of the progress is proving slower and lower than expectations. 4. Wingstop (WING) downgraded to Neutral from Buy at Goldman Sachs with analyst Karen Holthouse saying she continues to view the company's comps and unit growth fundamentals favorably but she recommends taking profits at current share levels. 5. AAR Corp. (AIR) downgraded to Hold from Buy at SunTrust with analyst Michael Ciarmoli saying he is maintaining a bullish view on the aero aftermarket with an opportunity for AAR Corp to exploit its position while also reaping benefits from its INL Global Aviation Support Services contract, but he also believes that the company's near-term growth will come under pressure from its maintenance, repair, and overhaul, or MRO, segment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/18
ADAM
07/11/18
NO CHANGE
Target $52
ADAM
Buy
AAR Corp. price target raised to $52 from $48 at Canaccord
Canaccord analyst Ken Herbert maintained a Buy rating on AAR Corp and raised his price target to $52 from $48, telling investors in a research note that the company's Q4 adjusted EPS of 52c was slightly ahead of his 50c estimate, but consistent with prior guidance, with revenues growing 5% from the same quarter last year. Herbert says management indicated that the INL/A contract ramp up is on track, and he continues to see a significant step-up in FY19 EPS and free cash flow, which should be positive for the stock.
FDX FedEx
$181.50

-0.92 (-0.50%)

02/22/19
RILY
02/22/19
NO CHANGE
RILY
Stamps.com should return to high single-digit growth, says B. Riley FBR
B. Riley FBR analyst Zach Cummins lowered his price target for Stamps.com (STMP) to $130 from $300 after the company announced the discontinuation of its partnership with the U.S. Postal Service. The stock in premarket trading is down 47%, or $93.07, to $105.01. The analyst also removed the shares from his firm's Alpha Generator list. However, he keeps a Buy rating on the shares. While cutting his estimates substantially on the news, Cummins believes Stamps.com can return to high single-digit growth with adjusted EBITDA margins near 30% in fiscal 2020. Stamps.com should be able to leverage its relationships, integrations, and volumes across to the industry to secure revenue share agreements with the likes of FedEx (FDX), UPS (UPS), or even Amazon.com (AMZN), Cummins tells investors in a research note.
02/19/19
MSCO
02/19/19
DOWNGRADE
Target $71
MSCO
Equal Weight
Morgan Stanley downgrades XPO Logistics, says M&A 'off the table'
As previously reported, Morgan Stanley analyst Ravi Shanker downgraded XPO Logistics (XPO) to Equal Weight from Overweight and lowered his price target for the shares to $71 from $116, stating that the company's 2019 guidance and sudden loss of its largest customer with virtually no notice has raised questions on forward visibility. M&A potential had made it his top pick previously, but now M&A is "off the table," said Shanker, who thinks confidence in the company's near-term trajectory may take time to recover. The analyst, who did not name the customer that he believes XPO recently lost, added he believes the customer aggressively insourcing its business away from XPO has "a significant negative read-across to other companies in the sector that are exposed to the same customer," particularly UPS (UPS), FedEx (FDX) and C.H. Robinson (CHRW). Other analysts have speculated that Amazon (AMZN) was the large customer lost by XPO.
02/15/19
JPMS
02/15/19
NO CHANGE
Target $78
JPMS
Overweight
JPMorgan cuts XPO Logistics target to $78, removes from Focus List
JPMorgan analyst Brian Ossenbeck lowered his price target for XPO Logistics (XPO) to $78 from $84 and removed the stock from his firm's Analyst Focus List following the company's Q4 results. The analyst expects XPO shares will be under pressure as the market digests a second guidance cut in as many months from "persistent uncertainty" in Europe combined with the recent loss of a large customer. Ossenbeck believes the shipper that is paring down its parcel injection, brokerage, last mile, and logistics activity with XPO is Amazon (AMZN). The market will interpret the XPO contract loss as Amazon taking capacity in-house which is negative for FedEx (FDX) and UPS (UPS), the analyst tells investors in a research note. He lowered his price target for XPO but keeps an Overweight rating on the name.
03/07/19
SBSH
03/07/19
NO CHANGE
Target $210
SBSH
Buy
FedEx price target lowered to $210 from $225 at Citi
Citi analyst Christian Wetherbee lowered his Q3 earnings per share estimate for FedEx to $3.05, which is 10c below consensus, from $3.28 ahead of the company's results. The reduced estimate reflects a softer outlook for Express related to slower International trends and ongoing profit headwinds from the TNT integration, as well as somewhat lower profit growth at Freight. The analyst ultimately sees value in FedEx shares given the "significantly" lowered expectations for TNT, but he acknowledges that "real clarity" may not be achieved until the company provides a full accounting of TNT. Wetherbee cut his price target for FedEx to $210 from $225 and keeps a Buy rating on the name.
FNV Franco-Nevada
$75.64

0.035 (0.05%)

07/10/18
MACQ
07/10/18
DOWNGRADE
MACQ
Neutral
Franco-Nevada downgraded to Neutral from Outperform at Macquarie
10/10/18
LEHM
10/10/18
INITIATION
Target $70
LEHM
Overweight
Franco-Nevada initiated with an Overweight at Barclays
Barclays analyst Matthew Murphy started Franco-Nevada with an Overweight rating and $70 price target. The analyst rolled out coverage on the North American mining sector with a positive outlook. The current dollar-positive macro dynamic has taken its toll on mining equities, offering investors an attractive entry point to the sector, Murphy tells investors in a research note.
07/18/18
DESJ
07/18/18
UPGRADE
DESJ
Hold
Franco-Nevada upgraded to Hold from Sell at Desjardins
PRNB Principia Biopharma
$36.88

0.48 (1.32%)

10/09/18
BARD
10/09/18
INITIATION
Target $50
BARD
Outperform
Principia Biopharma initiated with an Outperform at Baird
Baird analyst Brian Skorney started Principia Biopharma (PRNB) with an Outperform rating and $50 price target, stating that its BTK inhibitor partnered with Sanofi (SNY) for multiple sclerosis has blockbuster potential. He also believes PRN1008, which is entering Phase 3, has a worldwide opportunity over $500M in pemphigus that would also open the door for a host of other indications.
10/09/18
LEER
10/09/18
INITIATION
Target $34
LEER
Outperform
Principia Biopharma initiated with an Outperform on sales forecast at Leerink
Leerink analyst Geoffrey Porges started Principia Biopharma with an Outperform rating and $34 price target. The analyst cited his sales forecast for lead asset PRN1008 in orphan diseases, pemphigus and immune thrombocytopenia purpura, which combined he believes can reach peak sales of about $550M risk-adjusted at 65% and 35% probability-of-success, respectively.
10/09/18
WELS
10/09/18
INITIATION
Target $45
WELS
Outperform
Principia Biopharma initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Principia Biopharma with an Outperform rating and $45 price target. The analyst views the company's drug chemistry platform as "highly leveragable" and feels its lead product targeting BTK for autoimmune disease is differentiated.
10/09/18
LEER
10/09/18
INITIATION
Target $34
LEER
Outperform
Principia Biopharma initiated with an Outperform at Leerink
Leerink started Principia Biopharma with an Outperform rating and $34 price target.

TODAY'S FREE FLY STORIES

MAT

Mattel

$13.25

0.95 (7.72%)

, F

Ford

$10.17

0.76 (8.08%)

09:55
04/26/19
04/26
09:55
04/26/19
09:55
Options
Early notable gainers among liquid option names on April 26th »

Notable gainers among…

MAT

Mattel

$13.25

0.95 (7.72%)

F

Ford

$10.17

0.76 (8.08%)

VRSN

VeriSign

$198.28

9.04 (4.78%)

EQT

EQT Corporation

$20.85

0.685 (3.40%)

COF

Capital One

$91.94

3.85 (4.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 02

    May

  • 03

    May

  • 09

    May

  • 16

    May

  • 23

    May

  • 11

    Jun

  • 12

    Jun

  • 24

    Jul

  • 23

    Oct

09:50
04/26/19
04/26
09:50
04/26/19
09:50
General news
U. Michigan sentiment preview: »

U. Michigan sentiment…

RL

Ralph Lauren

$130.62

0.885 (0.68%)

09:48
04/26/19
04/26
09:48
04/26/19
09:48
Upgrade
Ralph Lauren rating change  »

Follow-up: Ralph Lauren…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

HSY

Hershey

$122.70

0.27 (0.22%)

09:48
04/26/19
04/26
09:48
04/26/19
09:48
Recommendations
Hershey analyst commentary  »

Hershey price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

USD

VeriSign Inc

$50.70

(0.00%)

09:47
04/26/19
04/26
09:47
04/26/19
09:47
Hot Stocks
VeriSign Inc falls -6.9% »

VeriSign Inc is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTV

Fortive

$80.98

-6.78 (-7.73%)

09:47
04/26/19
04/26
09:47
04/26/19
09:47
Hot Stocks
Fortive falls -7.8% »

Fortive is down -7.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATEN

A10 Networks

$6.31

-0.97 (-13.32%)

09:47
04/26/19
04/26
09:47
04/26/19
09:47
Hot Stocks
A10 Networks falls -13.6% »

A10 Networks is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRO

Pros Holdings

$45.06

(0.00%)

09:47
04/26/19
04/26
09:47
04/26/19
09:47
Hot Stocks
Pros Holdings rises 9.3% »

Pros Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

ENVA

Enova International

$30.38

3.85 (14.51%)

09:47
04/26/19
04/26
09:47
04/26/19
09:47
Hot Stocks
Enova International rises 14.4% »

Enova International is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 09

    May

  • 30

    May

  • 13

    Nov

GRUB

GrubHub

$76.84

7.01 (10.04%)

09:47
04/26/19
04/26
09:47
04/26/19
09:47
Hot Stocks
GrubHub rises 10.3% »

GrubHub is up 10.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 28

    May

  • 05

    Jun

SPY

SPDR S&P 500 ETF Trust

$292.02

-0.1 (-0.03%)

, SPX

S&P 500

$0.00

(0.00%)

09:46
04/26/19
04/26
09:46
04/26/19
09:46
Hot Stocks
Kudlow says trade deal with China 'is not done' »

Larry Kudlow, director of…

SPY

SPDR S&P 500 ETF Trust

$292.02

-0.1 (-0.03%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
04/26/19
04/26
09:45
04/26/19
09:45
General news
Consumer Sentiment Index to be reported at 10:00 »

Consumer Sentiment Index…

SBUX

Starbucks

$77.07

(0.00%)

09:41
04/26/19
04/26
09:41
04/26/19
09:41
Recommendations
Starbucks analyst commentary  »

Starbucks price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

09:40
04/26/19
04/26
09:40
04/26/19
09:40
On The Fly
The Intersection: Crypto and Wall Street This Week »

As bitcoin, ethereum and…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

SSNLF

Samsung

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

JPM

JPMorgan

$113.62

(0.00%)

AMD

AMD

$27.66

(0.00%)

NVDA

Nvidia

$186.84

(0.00%)

OSTK

Overstock.com

$13.13

(0.00%)

DPW

DPW Holdings

$0.22

(0.00%)

KODK

Kodak

$2.38

(0.00%)

IDEX

Ideanomics

$1.84

(0.00%)

RIOT

Riot Blockchain

$5.90

(0.00%)

TEUM

Pareteum

$3.90

(0.00%)

SRAX

Social Reality

$4.80

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 30

    Apr

  • 07

    May

  • 09

    May

  • 14

    May

  • 15

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 28

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

  • 10

    Jun

  • 11

    Jun

  • 24

    Jun

  • 25

    Jun

  • 16

    Jul

F

Ford

$9.41

(0.00%)

, JNPR

Juniper

$28.12

(0.00%)

09:40
04/26/19
04/26
09:40
04/26/19
09:40
Options
Unusually active option classes on open April 26th »

Unusual total active…

F

Ford

$9.41

(0.00%)

JNPR

Juniper

$28.12

(0.00%)

WMT

Walmart

$103.52

(0.00%)

INTC

Intel

$57.59

(0.00%)

GRUB

GrubHub

$69.83

(0.00%)

AMZN

Amazon.com

$1,902.53

(0.00%)

MRVL

Marvell

$25.42

(0.00%)

XOM

Exxon Mobil

$82.25

(0.00%)

KR

Kroger

$25.77

(0.00%)

WDC

Western Digital

$52.95

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 29

    Apr

  • 01

    May

  • 03

    May

  • 06

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 14

    May

  • 16

    May

  • 16

    May

  • 21

    May

  • 22

    May

  • 28

    May

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 24

    Jul

  • 25

    Jul

  • 23

    Oct

  • 13

    Nov

09:40
04/26/19
04/26
09:40
04/26/19
09:40
General news
Fed Policy Outlook: analysts continue to take issue with the market's dovish bet »

Fed Policy Outlook:…

AAPL

Apple

$205.28

-1.82 (-0.88%)

09:39
04/26/19
04/26
09:39
04/26/19
09:39
Recommendations
Apple analyst commentary at OTR Global »

Apple incentives not much…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 03

    Jun

HIBB

Hibbett Sports

$20.53

0.13 (0.64%)

, TSCO

Tractor Supply

$105.09

1 (0.96%)

09:37
04/26/19
04/26
09:37
04/26/19
09:37
Hot Stocks
Hibbett Sports names Christine Skold as Interim CFO, effective April 26 »

Hibbett Sports (HIBB)…

HIBB

Hibbett Sports

$20.53

0.13 (0.64%)

TSCO

Tractor Supply

$105.09

1 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 15

    May

  • 23

    May

  • 25

    Jul

  • 13

    Nov

SBUX

Starbucks

$77.07

0.65 (0.85%)

09:37
04/26/19
04/26
09:37
04/26/19
09:37
Hot Stocks
Starbucks CEO says competitor discounts in China not sustainable »

Kevin Johnson is speaking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$161.03

-0.47 (-0.29%)

09:36
04/26/19
04/26
09:36
04/26/19
09:36
Recommendations
Visa analyst commentary at BMO Capital »

Visa price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

  • 29

    May

  • 05

    Jun

WNS

WNS Holdings

$56.71

0.26 (0.46%)

09:36
04/26/19
04/26
09:36
04/26/19
09:36
Recommendations
WNS Holdings analyst commentary at Barrington »

WNS Holdings price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

ANTM

Anthem

$256.01

5 (1.99%)

, CVS

CVS Health

$53.24

0.31 (0.59%)

09:34
04/26/19
04/26
09:34
04/26/19
09:34
Recommendations
Anthem, CVS Health analyst commentary at Cleveland Research »

Anthem won Blue Cross of…

ANTM

Anthem

$256.01

5 (1.99%)

CVS

CVS Health

$53.24

0.31 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

  • 01

    May

  • 07

    May

  • 15

    May

  • 16

    May

  • 19

    May

  • 29

    May

  • 18

    Jun

RL

Ralph Lauren

$129.74

-2.31 (-1.75%)

09:34
04/26/19
04/26
09:34
04/26/19
09:34
Upgrade
Ralph Lauren rating change  »

Ralph Lauren upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

SFLY

Shutterfly

$42.30

-0.65 (-1.51%)

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Upgrade
Shutterfly rating change at Raymond James »

Shutterfly upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

HTBK

Heritage Commerce

09:32
04/26/19
04/26
09:32
04/26/19
09:32
Downgrade
Heritage Commerce rating change at Brean Capital »

Heritage Commerce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.